The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 101–200 of 1,002
de Almeida, R. B. M., Barbosa, D. B., do Bomfim, M. R., Amparo, J. A. O., Andrade, B. S., Costa, S. L., Rosa, J. M. C., Cruz, J. N., Santos, C. B. R., Leite, F. H. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16010095 · Cited by 86
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 85
Oliyaei, N., Moosavi‐Nasab, M., Tanideh, N., & Iraji, A. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.018 · Cited by 85
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends
Zeng, H., Qi, Y., Zhang, Z., Liu, C., Peng, W., & Zhang, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.01.014 · Cited by 83
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Haghighijoo, Z., Zamani, L., Moosavi, F., & Emami, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113949 · Cited by 83
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias
Balázs, N., Bereczki, D., & Kovács, T. (2021) · Ideggyógyászati Szemle · doi:10.18071/isz.74.0379 · Cited by 83
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 80
The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies
Takeuchi, Y., Nagy, A. J., Barcsai, L., Li, Q., Ohsawa, M., Mizuseki, K., & Berényi, A. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.701080 · Cited by 81
Hanna Al-Shaikh, F. S., Duara, R., Crook, J. E., Lesser, E. R., Schaeverbeke, J., Hinkle, K. M., Ross, O. A., Ertekin-Taner, N., Pedraza, O., Dickson, D. W., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3606 · Cited by 80
Da, Z., Yang, K., Guo, H., Zeng, J., Wang, S., Xu, H., Ge, A., Zeng, L., Chen, S., & Ge, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114312 · Cited by 80
Olajide, O. J., Suvanto, M. E., & Chapman, C. A. (2021) · Biology Open · doi:10.1242/bio.056796 · Cited by 80
Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer’s Disease
Wolinsky, D., Drake, K., & Bostwick, J. R. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0978-8 · Cited by 79
Membrane Interactions and Toxicity by Misfolded Protein Oligomers
Gonzalez-Garcia, M., Fusco, G., & Simone, A. D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.642623 · Cited by 78
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
Monfared, A. A. T., Phan, N. T. N., Pearson, I. V., Mauskopf, J., Cho, M., Zhang, Q., & Hampel, H. J. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00504-6 · Cited by 77
Self-citationPhage display derived peptides for Alzheimer's disease therapy and diagnosis
Zhang, X., Zhang, X., Gao, H., & Qing, G. (2022) · Theranostics · doi:10.7150/thno.68636 · Cited by 78
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.020 · Cited by 77
Okello, E. J., & Mather, J. (2020) · Nutrients · doi:10.3390/nu12041090 · Cited by 76
Implication of EEG theta/alpha and theta/beta ratio in Alzheimer’s and Lewy body disease
Baik, K., Jung, J. H., Jeong, S. H., Chung, S. J., Yoo, H. S., Lee, P. H., Sohn, Y. H., Kang, S. W., & Ye, B. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-21951-5 · Cited by 76
Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
Wirths, O., & Zampar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218144 · Cited by 75
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
BackgroundAdvances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 75
Panax Ginseng in the treatment of Alzheimer's disease and vascular dementia
Wang, Z., Zhang, Z., Liu, J., Guo, M.-D., & Li, H. (2023) · Journal of Ginseng Research · doi:10.1016/j.jgr.2023.03.001 · Cited by 75
Xu, J. F., Wang, F., Guo, J., Xu, C., Cao, Y., Fang, Z., & Wang, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062071 · Cited by 75
Metabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain
Jankowska-Kulawy, A., Klimaszewska‐Łata, J., Gul‐Hinc, S., Ronowska, A., & Szutowicz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710073 · Cited by 76
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 74
Natural Polyphenolic Nanodots for Alzheimer's Disease Treatment
Yang, P., Huang, Q., Zhang, J., Li, Y., Gao, H., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308393 · Cited by 74
Emerging Role of Neuron‐Glia in Neurological Disorders: At a Glance
Rahman, M. M., Islam, M. R., Yamin, M., Islam, M. M., Sarker, M. T., Meem, A. F. K., Akter, A., Emran, T. B., Cavalu, S. D., & Sharma, R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3201644 · Cited by 75
Regulators of cholinergic signaling in disorders of the central nervous system
Winek, K., Soreq, H., & Meisel, A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15332 · Cited by 73
Forebrain Cholinergic Signaling Regulates Innate Immune Responses and Inflammation
Lehner, K. R., Silverman, H. A., Addorisio, M. E., Roy, A., Al-Onaizi, M. A., Levine, Y., Olofsson, P. S., Chavan, S. S., Gros, R., Nathanson, N. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00585 · Cited by 73
Lu, M., Ji, W., Chen, H., Sun, Y., Zhao, X., Wang, F., Shi, Y., Hu, Y.-N., Liu, B.-X., Wu, J., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.650103 · Cited by 73
Lv, J., Lü, C., Jiang, N., Wang, H., Huang, H. M., Chen, Y., Li, Y., & Liu, X. (2020) · Phytotherapy Research · doi:10.1002/ptr.6804 · Cited by 72
Smit, T., Deshayes, N. A. C., Borchelt, D. R., Kamphuis, W., Middeldorp, J., & Hol, E. M. (2021) · Glia · doi:10.1002/glia.23981 · Cited by 71
Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review
Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 72
Do Nicotinic Receptors Modulate High-Order Cognitive Processing?
Koukouli, F., & Changeux, J. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.06.001 · Cited by 71
New insight into protein glycosylation in the development of Alzheimer’s disease
Zhao, J., & Lang, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01617-5 · Cited by 70
Jasiecki, J., & Wasąg, B. (2019) · Biomolecules · doi:10.3390/biom9100592 · Cited by 69
Morrone, C. D., Raghuraman, R., Hussaini, S. A., & Yu, W. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00617-4 · Cited by 69
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0797-2 · Cited by 68
Self-citationPathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Paul, R. K., Mazumder, M. K., Nath, J., Deb, S., Paul, S., Bhattacharya, P., & Borah, A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104823 · Cited by 68
Sphingolipid control of cognitive functions in health and disease
Kalinichenko, L. S., Gulbins, E., Kornhuber, J., & Müller, C. P. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101162 · Cited by 68
Rykov, Y. G., Patterson, M. D., Gangwar, B. A., Jabar, S. B., Leonardo, J., Ng, K. P., & Kandiah, N. (2024) · BMC Medicine · doi:10.1186/s12916-024-03252-y · Cited by 68
Liu, D., Zhang, H., Wang, Y., Liu, W., Yin, G., Wang, D., Li, J., Shi, T., & Wang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114044 · Cited by 68
Şenol, H., Ghaffari‐Moghaddam, M., Toraman, G. Ö. A., & Güller, U. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136804 · Cited by 68
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders
Tiepolt, S., Meyer, P., Patt, M., Deuther‐Conrad, W., Hesse, S., Barthel, H., & Sabri, O. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263198 · Cited by 67
Potential of Caffeine in Alzheimer’s Disease—A Review of Experimental Studies
Londzin, P., Zamora, M., Kąkol, B., Taborek, A., & Folwarczna, J. (2021) · Nutrients · doi:10.3390/nu13020537 · Cited by 67
Huber, N., Korhonen, S., Hoffmann, D. B., Leskelä, S., Rostalski, H., Remes, A. M., Honkakoski, P., Solje, E., & Haapasalo, A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01384-8 · Cited by 67
Jiang, X., Zhang, Z., Zuo, J., Wu, C., Zha, L., Xu, Y., Wang, S., Shi, J., Liu, X., Zhang, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113735 · Cited by 67
Martins, B., Vieira, M., Delerue-Matos, C. M., Grosso, C., & Soares, C. M. D. (2022) · Marine Drugs · doi:10.3390/md20060362 · Cited by 66
Liu, W., Li, J., Yang, M., Ke, X., Dai, Y., Lin, H., Wang, S., Chen, L., & Tao, J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00994-w · Cited by 66
Aβ promotes CD38 expression in senescent microglia in Alzheimer’s disease
Hu, Y., Huang, Y., Xing, S., Chen, C., Shen, D., & Chen, J. (2022) · Biological Research · doi:10.1186/s40659-022-00379-1 · Cited by 65
Si, G., & Álvarez, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21722 · Cited by 65
Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective
Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., Hernandez, F., Geerts, H., Vergallo, A., (APMI), A. P. M. I., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190197 · Cited by 65
Self-citationGhotbi, G., Mahdavi, M. R., Najafi, Z., Moghadam, F. H., Hamzeh‐Mivehroud, M., Davaran, S., & Dastmalchi, S. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104186 · Cited by 66
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 65
Sun, T., Zhen, T., Harakandi, C. H., Wang, L., Guo, H., Chen, Y., & Sun, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116569 · Cited by 64
Treating disorders across the lifespan by modulating cholinergic signaling with galantamine
Metz, C. N., & Pavlov, V. A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15243 · Cited by 64
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
“In post-mortem Alzheimer’s disease brain tissue, the expression levels of the M2 mAChRs are decreased but there are no significant changes to the expression level of the M1 mAChRs when compared to normal aged brain tissue (Nordberg and Winblad, 1986; Flynn et al., 1991; Hampel et al., 2018); an important consideration…”
BackgroundGinsenoside and Its Therapeutic Potential for Cognitive Impairment
Feng, H., Xue, M., Deng, H., Cheng, S., Hu, Y., & Zhou, C. (2022) · Biomolecules · doi:10.3390/biom12091310 · Cited by 63
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 63
Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 63
Giorgi, F. S., Galgani, A., Puglisi‐Allegra, S., Limanaqi, F., Busceti, C. L., & Fornai, F. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24718 · Cited by 63
Regulation of Melatonin and Neurotransmission in Alzheimer’s Disease
Roy, J., Tsui, K. C., Ng, J., Fung, M., & Lim, L. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136841 · Cited by 63
Huang, P., Zhang, L., Tan, Y., & Chen, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00337-1 · Cited by 63
Wdowiak, K., Rosiak, N., Tykarska, E., Żarowski, M., Płazińska, A., Płaziński, W., & Cielecka‐Piontek, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074000 · Cited by 63
Mascarenhas, A. M. S., de Almeida, R. B. M., Neto, M. F. D. A., Mendes, G. O., Cruz, J. N., Santos, C. B. R., Botura, M. B., & Leite, F. H. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1796791 · Cited by 63
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Acetylcholine modulates the temporal dynamics of human theta oscillations during memory
Gedankien, T., Tan, R. J., Qasim, S. E., Moore, H. C., McDonagh, D. L., Jacobs, J., & Lega, B. C. (2023) · Nature Communications · doi:10.1038/s41467-023-41025-y · Cited by 62
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
Barba, L., Abu‐Rumeileh, S., Barthel, H., Massa, F., Foschi, M., Bellomo, G., Gaetani, L., Thal, D. R., Parnetti, L., & Otto, M. (2024) · Brain · doi:10.1093/brain/awae203 · Cited by 62
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Receptors for pro‐resolving mediators are increased in Alzheimer's disease brain
Emre, C., Hjorth, E., Bharani, K., Carroll, S., Granholm, A., & Schultzberg, M. (2020) · Brain Pathology · doi:10.1111/bpa.12812 · Cited by 60
“Drugs enhancing the function of BF cholinergic neurons represent one out of only a few existing drug intervention strategies for AD (34), demonstrating the strong contribution of these neurons to memory and learning processes.”
BackgroundDiagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 60
Interaction of acetylcholine and oxytocin neuromodulation in the hippocampus
Zhang, Y., Karadas, M., Liu, J., Gu, X., Vöröslakos, M., Li, Y., Tsien, R. W., & Buzsáki, G. (2024) · Neuron · doi:10.1016/j.neuron.2024.02.021 · Cited by 60
Progress in Target Drug Molecules for Alzheimer's Disease
Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 60
Panax notoginseng saponins and their applications in nervous system disorders: a narrative review
Qu, J., Xu, N., Zhang, J., Geng, X., & Zhang, R. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6909 · Cited by 60
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 60
Yi, P., Zhang, Z., Huang, S., Huang, J., Peng, W., & Yang, J. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1817103 · Cited by 60
Choline Intake Correlates with Cognitive Performance among Elder Adults in the United States
Liu, L., Qiao, S., Zhuang, L., Xu, S., Chen, L., Lai, Q., & Wang, W. (2021) · Behavioural Neurology · doi:10.1155/2021/2962245 · Cited by 59
“Dysregulation of cholinergic neurotransmission is linked to several cognitive disorders, such as Alzheimer’s disease (AD), the most prevalent age-related neurodegenerative disease [9].”
BackgroundAbuelezz, N. Z., Nasr, F. E., AbdulKader, M. A., Bassiouny, A. R., & Zaky, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.743573 · Cited by 59
Mandour, D. A., Bendary, M., & Alsemeh, A. E. (2021) · Journal of Molecular Histology · doi:10.1007/s10735-021-09998-6 · Cited by 59
Molecularly defined and functionally distinct cholinergic subnetworks
Li, X., Yu, H., Zhang, B., Li, L., Chen, W., Yu, Q., Huang, X., Ke, X., Wang, Y., Jing, W., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.08.025 · Cited by 58
El-Ganainy, S. O., Soliman, O., Ghazy, A. A., Allam, M., Elbahnasi, A. I., Mansour, A. M., & Gowayed, M. A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03624-x · Cited by 58
New insights in animal models of neurotoxicity-induced neurodegeneration
Sanfeliu, C., Bartra, C., Sunol, C. E., & Rodríguez-Farré, E. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1248727 · Cited by 59
Iqbal, D., Alsaweed, M., Jamal, Q. M. S., Asad, M. R., Rizvi, S. M. D., Rizvi, M. R., Albadrani, H. M., Hamed, M., Jahan, S., & Alyenbaawi, H. (2023) · Biomolecules · doi:10.3390/biom13111613 · Cited by 57
Boiangiu, R. Ş., Mihăşan, M., Gorgan, L., Stache, A. B., & Hriţcu, L. (2021) · Antioxidants · doi:10.3390/antiox10020212 · Cited by 57
Treating Alzheimer’s disease using nanoparticle-mediated drug delivery strategies/systems
Roghani, A. K., Garcia, R. I., Roghani, A., Reddy, A. P., Khemka, S., Reddy, R. P., Pattoor, V., Jacob, M., Reddy, P. H., & Sehar, U. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102291 · Cited by 59
Song, Y., Wang, X., Wang, X., Wang, J., Hao, Q., Hao, J., & Hou, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8844455 · Cited by 57
Park, S., & Wu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113574 · Cited by 56
Xu, H., Zhou, Q., Liu, B., Cheng, K., Chen, F., & Wang, M. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c04049 · Cited by 57
On the Use of TMS to Investigate the Pathophysiology of Neurodegenerative Diseases
Rawji, V., Latorre, A., Sharma, N., Rothwell, J. C., & Rocchi, L. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.584664 · Cited by 56
Liu, W., Liu, X., Liu, W., Gao, Y., Wu, L., Huang, Y., Chen, H., Li, D., Zhou, L., Wang, N., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114095 · Cited by 56
Pimpinella, D., Mastrorilli, V., Giorgi, C., Coemans, S., Lecca, S., Lalive, A. L., Ostermann, H., Fuchs, E. C., Monyer, H., Mele, A., et al. (2021) · eLife · doi:10.7554/elife.65580 · Cited by 55
Sun, P., Zhu, H., Li, X., Shi, W., Guo, Y., Du, X., Zhang, L., Su, L., & Qin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911560 · Cited by 55
Biomarker-guided clustering of Alzheimer's disease clinical syndromes
Toschi, N., Lista, S., Baldacci, F., Cavedo, E., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., dos Santos, A. M., Epelbaum, S., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.032 · Cited by 54
Self-citationRodríguez, M. H., Arciniega-Martínez, I. M., García-Marín, I. D., Correa‐Basurto, J., & Rosales‐Hernández, M. C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02009-x · Cited by 54
Shen, Y., Zhao, M., Zhao, P., Meng, L., Zhang, Y., Zhang, G., Taishi, Y., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408462 · Cited by 55
Chen, X., Salehi, A., Pearn, M. L., Overk, C., Nguyen, P. D., Kleschevnikov, A. M., Maccecchini, M., & Mobley, W. C. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12185 · Cited by 54
Jabir, N. R., Shakil, S., Tabrez, S. S. M., Khan, M. S., Rehman, M. T., & Ahmed, A. B. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1784796 · Cited by 54
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53
“All AChEIs are approved by the Food and Drug Administration (FDA) for mild-to-moderate AD [19].”
Background
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.